Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

Stock Information for Clene Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clene Inc.

Clene to Provide CNM-Au8® ALS Program Update
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Clene to Present at the Emerging Growth Conference
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.